检验医学 ›› 2018, Vol. 33 ›› Issue (1): 1-9.DOI: 10.3969/j.issn.1673-8640.2018.01.0001
• 专家论坛 • 下一篇
收稿日期:
2017-05-11
发布日期:
2018-01-31
作者简介:
null作者简介:张 岩,女,1976年生,博士,主要从事质谱技术在临床的应用研究及临床实验室的管理工作。
Received:
2017-05-11
Published:
2018-01-31
摘要:
质谱(MS)技术具有较高的特异性、灵敏度及可同时检测多个化合物的能力,对其的应用正成为临床实验室一个快速发展的领域。目前,已有多种MS分析仪应用于临床实验室,其检测性能正在快速提升。文章对MS技术作了基本介绍,包括临床实验室MS检测的相关仪器、电离技术及样品制备等,并就临床实验室开展MS检测所面临的挑战及应用前景进行探讨。
中图分类号:
张岩, ThomasJackson. 临床实验室质谱检测原理[J]. 检验医学, 2018, 33(1): 1-9.
ZHANG Yan, Thomas Jackson. Clinical mass spectrometry:principles of mass spectrometry for clinical laboratories[J]. Laboratory Medicine, 2018, 33(1): 1-9.
名称 | 色谱法 | 待测物类别 | 待测物分子质量 | 优点 | 缺点 |
---|---|---|---|---|---|
EI | GC | 非极性,可挥发 | 低-中 | 质量谱重复性高 | 与LC不兼容 |
CI | GC | 非极性,可挥发 | 低-中 | GC兼容样品信息 | 与LC不兼容 |
ESI | LC,SFC,CE | 极性 | 中-高 | 与许多生物样品兼容 | 受限于电离抑制 |
APCI | LC,SFC,CE | 极性、极性较小 | 较低-中 | 较ESI稳定 | 不及ESI敏感 |
APPI | LC, SFC, CE | 含芳香基团 | 较低-中 | 高信噪比 | 只能用于含芳香基团物质的检测 |
表1 临床化学色谱分析常用电离技术的比较
名称 | 色谱法 | 待测物类别 | 待测物分子质量 | 优点 | 缺点 |
---|---|---|---|---|---|
EI | GC | 非极性,可挥发 | 低-中 | 质量谱重复性高 | 与LC不兼容 |
CI | GC | 非极性,可挥发 | 低-中 | GC兼容样品信息 | 与LC不兼容 |
ESI | LC,SFC,CE | 极性 | 中-高 | 与许多生物样品兼容 | 受限于电离抑制 |
APCI | LC,SFC,CE | 极性、极性较小 | 较低-中 | 较ESI稳定 | 不及ESI敏感 |
APPI | LC, SFC, CE | 含芳香基团 | 较低-中 | 高信噪比 | 只能用于含芳香基团物质的检测 |
样品制备技术 | 优点 | 缺点 | 样品适用性 |
---|---|---|---|
稀释后直接进样 | 简单、成本低廉、快速 | 清除不彻底、非选择性、样品需稀释 | 尿液 |
蛋白沉淀 | 简单、成本低廉、快速 | 极低选择性、无法消除基质干扰 | 血液、血浆、 血清 |
液-液萃取 | 具有分析物类别特异性、可放大浓度 | 难以实现自动化 | 尿液、血浆、 血清、唾液 |
固相萃取法去除 蛋白质及脂质 | 简单、快速(如实现自动化)、易于 开发、可放大浓度、清除彻底 | 极低选择性 | 血液、血浆、 血清 |
固相萃取 | 方法开发复杂、耗材成本最高 | 所有种类样品 | |
快速(如实现自动化)、回收率高、具 分析物类别特异性、可放大浓度 |
表2 常用LC-MS/MS样品制备技术的比较
样品制备技术 | 优点 | 缺点 | 样品适用性 |
---|---|---|---|
稀释后直接进样 | 简单、成本低廉、快速 | 清除不彻底、非选择性、样品需稀释 | 尿液 |
蛋白沉淀 | 简单、成本低廉、快速 | 极低选择性、无法消除基质干扰 | 血液、血浆、 血清 |
液-液萃取 | 具有分析物类别特异性、可放大浓度 | 难以实现自动化 | 尿液、血浆、 血清、唾液 |
固相萃取法去除 蛋白质及脂质 | 简单、快速(如实现自动化)、易于 开发、可放大浓度、清除彻底 | 极低选择性 | 血液、血浆、 血清 |
固相萃取 | 方法开发复杂、耗材成本最高 | 所有种类样品 | |
快速(如实现自动化)、回收率高、具 分析物类别特异性、可放大浓度 |
[1] | YOST R A, ENKE C G.Triple quadrupole mass spectrometry for direct mixture analysis and structure elucidation[J]. Anal Chem, 1979,51(12):1251-1264. |
[2] | SHACKLETON C.Clinical steroid mass spectrometry: a 45-year history culminating in HPLC-MS/MS becoming an essential tool for patient diagnosis[J]. J Steroid Biochem Mol Biol,2010,121(3-5): 481-490. |
[3] | LEHOTAY D C, CLARKE J T.Organic acidurias and related abnormalities[J]. Crit Rev Clin Lab Sci, 1995,32(4): 377-429. |
[4] | MILLINGTON D S, KODO N, NORWOOD D L, et al.Tandem mass spectrometry: a new method for acylcarnitine profiling with potential for neonatal screening for inborn errors of metabolism[J]. J Inherit Metab Dis, 1990,13(3): 321-324. |
[5] | BLAKLEY C R, VESTAL M L.Thermospray interface for liquid chromatography/mass spectrometry[J]. Anal Chem, 1983,55(4): 750-754. |
[6] | ADAWAY J E, KEEVIL B G, OWEN L J.Liquid chromatography tandem mass spectrometry in the clinical laboratory[J]. Ann Clin Biochem, 2015,52(Pt 1): 18-38. |
[7] | COTTER R J, SWATKOSKI S, BECKER L, et al.Time-of-flights and traps: from the Histone Code to Mars[J]. Eur J Mass Spectrom(Chichester), 2010, 16(3): 331-340. |
[8] | PLASS W R, DICKEL T, SCHEIDENBERGER C.Multiple-reflection time-of-flight mass spectrometry[J]. Int J Mass Spectrom,2013, 349-350 : 134-144. |
[9] | COMISAROW M B, MARSHALL A G.Frequency-sweep Fourier transform ion cyclotron resonance spectroscopy[J]. Chem Phys Lett, 1974,26(4): 489-490. |
[10] | COMISAROW M B, MARSHALL A G.Fourier transform ion cyclotron resonance spectroscopy[J]. Chem Phys Lett, 1974,25(2): 282-283. |
[11] | MAKAROV A.Electrostatic axially harmonic orbital trapping: a high-performance technique of mass analysis[J]. Anal Chem, 2000,72(6): 1156-1162. |
[12] | DE HOFFMANN E.Tandem mass spectrometry: a primer[J]. J Mass Spectrom, 1996,31(2): 129-137. |
[13] | KEBARLE P, VERKERK U H.A brief overview of the mechanisms involved in electrospray mass spectrometry[M].Weinheim:Wiley-VCH Verlag GmbH and Co. KGaA, 2010:1-35. |
[14] | GOHLKE R S.Time-of-flight mass spectrometry and gas-liquid partition chromatography[J]. Anal Chem, 1959,31: 535-541. |
[15] | GOHLKE R S, MCLAFFERTY F W.Early gas chromatography/mass spectrometry[J]. J Am Soc Mass Spectrom, 1993,4(5): 367-371. |
[16] | WILKINS C L, LAY J O.Identification of microorganisms by mass spectrometry[J]. Chem Anal, 2006,2006:169. |
[17] | TAKÁTS Z, WISEMAN J M, GOLOGAN B, et al. Mass spectrometry sampling under ambient conditions with desorption electrospray ionization[J]. Science, 2004,306(5695): 471-473. |
[18] | WAGNER M, TONOLI D, VARESIO E, et al.The use of mass spectrometry to analyze dried blood spots[J]. Mass Spectrom Rev, 2016,35(3): 361-438. |
[19] | RODUSHKIN I, ENGSTRÖM E, BAXTER D C. Isotopic analyses by ICP-MS in clinical samples[J]. Anal Bioanal Chem, 2013,405(9): 2785-2797. |
[20] | DELAFIORI J, RING G, FUREY A.Clinical applications of HPLC-ICP-MS element speciation: a review[J]. Talanta, 2016,153: 306-331. |
[21] | LUNDANES E, REUBSAET L, GREIBROKK T.Chromatography: basic principles, sample preparations and relate. Methods [M]. New Jersey:John Wiley and Sons,2013. |
[22] | HSIEH Y.Supercritical fluid chromatography-mass spectrometry[J]. Boca Raton:CRC Press,2010:277-296. |
[23] | PONTILLO C, FILIP S, BORRAS D M, et al.CE-MS-based proteomics in biomarker discovery and clinical application[J]. Proteomics Clin Appl, 2015,9(3-4): 322-334. |
[24] | GELL D A, GRANT R P, MACKAY J P.The detection and quantitation of protein oligomerization[J]. Adv Exp Med Biol, 2012,747: 19-41. |
[25] | LINGE K L, JARVIS K E.Quadrupole ICP-MS: introduction to instrumentation, measurement techniques and analytical capabilities[J]. Geostand Geoanal Res, 2009,33(4): 445-467. |
[26] | MEYER G M, MAURER H H, MEYER M R.Multiple stage MS in analysis of plasma, serum, urine and in vitro samples relevant to clinical and forensic toxicology[J]. Bioanalysis, 2016,8(5): 457-481. |
[27] | MESMIN C, VAN OOSTRUM J, DOMON B.Complexity reduction of clinical samples for routine mass spectrometric analysis[J]. Proteomics Clin Appl, 2016,10(4): 315-322. |
[28] | PERSONA K, MADEJ K, KNIHNICKI P, et al.Analytical methodologies for the determination of benzodiazepines in biological samples[J]. J Pharm Biomed Anal, 2015,113: 239-264. |
[29] | BOURGOGNE E, WAGNER M.Sample preparation and bioanalysis in mass spectrometry[J]. Ann Biol Clin(Paris), 2015,73(1): 11-23. |
[30] | FARHADI K, HATAMI M, MATIN A A.Microextraction techniques in therapeutic drug monitoring[J]. Biomed Chromatogr, 2012,26(8): 972-989. |
[31] | DEVENTER K, POZO O J, VERSTRAETE A G, et al.Dilute-and-shoot-liquid chromatography-mass spectrometry for urine analysis in doping control and analytical toxicology[J]. TrAC Trends Anal Chem, 2014,55: 1-13. |
[32] | FRITZ J S.Solid-phase extraction: principles, techniques and applications[J]. J Am Chem Society, 2000,122(49): 12411-12412. |
[33] | KUELPMANN W R, HANNAK D.Methods for clinical toxicological analysis[M]. Weinheim:Wiley-VCH Verlag GmbH and Co. KGaA, 2009:25-58. |
[34] | WUDY S A, HOMOKI J.Profiling steroids by gas chromatography-mass spectrometry: clinical applications[M]. Switzerland: S Karger AG, 2003:427-449. |
[35] | BAKER T C, HAN J, BORCHERS C H.Recent advancements in matrix-assisted laser desorption/ionization mass spectrometry imaging[J]. Curr Opin Biotechnol, 2017,43: 62-69. |
[36] | MARCINKOWSKA M, BARALKIEWICZ D.Multielemental speciation analysis by advanced hyphenated technique-HPLC/ICP-MS: a review[J]. Talanta, 2016,161: 177-204. |
[37] | THOMPSON B M, SCOTT B I, BOIANI J A.Understanding the Food and Drug Administration's jurisdiction over laboratory-developed tests and divisions between food, drug, and cosmetic act-regulated and Clinical Laboratory Improvement Amendments of 1988-regulated activities[J]. Clin Lab Med, 2016,36(3): 575-585. |
[38] | LEHMANN W D.A timeline of stable isotopes and mass spectrometry in the life sciences[J]. Mass Spectrom Rev, 2017,36(1): 58-85. |
[39] | ANNESLEY T M.Ion suppression in mass spectrometry[J]. Clin Chem, 2003,49(7): 1041-1044. |
[40] | VILJANTO M, SCARTH J, HINCKS P, et al.Application of testosterone to epitestosterone ratio to horse urine-a complementary approach to detect the administrations of testosterone and its pro-drugs in thoroughbred geldings[J]. Drug Test Anal, 2017,9(9): 1328-1336. |
[41] | CARTER G D, JONES J C, SHANNON J, et al.25-Hydroxyvitamin Dassays: potential interference from other circulating vitamin dmetabolites[J]. J Steroid Biochem Mol Biol, 2016,164: 134-138. |
[42] | ZHANG Y V, ROCKWOOD A.Impact of automation on mass spectrometry[J]. Clin Chim Acta, 2015,450: 298-303. |
[43] | FRENCH D, TERRAZAS E.The successful implementation of a licensed data management interface between a Sunquest(®) laboratory information system and an AB SCIEXTM mass spectrometer[J]. J Pathol Inform, 2013,4: 1. |
[44] | CORTELYOU-WARD K, RAMIREZ B, ROTARIUS T.The laboratory workforce shortage: a managerial perspective[J]. Health Care Manag (Frederick), 2011,30(2): 148-155. |
[45] | GARG U, ZHANG Y V.Mass spectrometry in clinical laboratory: applications in biomolecular analysis[J]. Methods Mol Biol, 2016,1378: 1-9. |
[46] | STOLL D R, CARR P W.Two-dimensional liquid chromatography: a state of the art tutorial[J]. Analytical Chem, 2017,89(1): 519-531. |
[47] | WEI D, LI M, KING K W, et al.Online and automated sample extraction[J]. Bioanalysis, 2015,7(17): 2227-2233. |
[48] | JOHNSON-DAVIS K L, JUENKE J M, THOMAS R L, et al. Everolimus method comparison between Waters MassTrakTM Immunosuppressants XE (IUO) kit and an in-house laboratory developed LC-MS/MS method in renal transplant patients[J]. Ann Clin Lab Sci, 2015,45(1): 27-31. |
[49] | SAITMAN A, METUSHI I G, MASON D S, et al.Evaluation of the Waters MassTrak LC-MS/MS assay for tacrolimus and a comparison to the Abbott architect immunoassay[J]. Ther Drug Monitor, 2016,38(3): 300-304. |
[50] | FERREIRA C R, YANNELL K E, JARMUSCH A K, et al.Ambient ionization mass spectrometry for point-of-care diagnostics and other clinical measurements[J]. Clin Chem, 2016,62(1): 99-110. |
[1] | 孟茜, 卫桢, 白建华, 郝晓柯, 曾宪飞. 患者数据指数加权移动均值法、室内质量控制室间化和自动审核在基层医疗机构临床实验室质量管理中的应用[J]. 检验医学, 2023, 38(9): 884-889. |
[2] | 谭春艳, 周莹, 莫志江. 定性测定性能评价卫生行业标准WS/T 505—2017附录B示例错误和纠正[J]. 检验医学, 2023, 38(6): 569-573. |
[3] | 周维, 诸佩超, 宋颖, 缪颖波, 赵强, 徐翀. 抗Xa因子活性室间质量评价调查品制备及应用[J]. 检验医学, 2023, 38(12): 1183-1185. |
[4] | 江雨航, 高源, 秦维超, 曾颜. 心脏人工瓣膜置换术后长奈瑟菌血流感染1例报道[J]. 检验医学, 2022, 37(8): 803-806. |
[5] | 张亚茹, 凌丽燕, 陈敏. EUCAST和CLSI微量肉汤稀释法白念珠菌体外药物敏感性试验结果比较[J]. 检验医学, 2022, 37(10): 974-978. |
[6] | 陈平, 陈婷婷. 基于ISO 15189质量体系的临床实验室风险控制系统的建立[J]. 检验医学, 2021, 36(8): 869-874. |
[7] | 王军杰, 马冰, 李轶, 闫文娟, 王山梅, 马琼, 张江峰, 许俊红, 袁有华. 质谱技术直接鉴定报阳血培养细菌可行性分析[J]. 检验医学, 2020, 35(7): 716-720. |
[8] | 徐黎明, 李牧, 龚倩. 六西格玛规则在实验室样本周转时间持续管理中的作用[J]. 检验医学, 2020, 35(7): 736-738. |
[9] | 付亚文, 杜玉珍, 高锋. CLSI临床实验室自动化标准概述[J]. 检验医学, 2020, 35(4): 370-373. |
[10] | 赖媛媛, 王宇婷, 陈家倪, 齐军, 何振业. SARS-CoV-2病原学特点、实验室检测及实验室生物安全防护[J]. 检验医学, 2020, 35(3): 278-281. |
[11] | 朱立岳, 胡雷光. 上海市静安区31个临床实验室现场评审不符合项分析[J]. 检验医学, 2019, 34(7): 651-655. |
[12] | 高锋. 临床实验室应注重肿瘤标志物的基础与开发研究[J]. 检验医学, 2019, 34(2): 95-97. |
[13] | Yan Victoria Zhang, Thomas Jackson. 质谱技术在临床实验室的应用[J]. 检验医学, 2019, 34(1): 1-7. |
[14] | 朱俊, 杨雪, 娄娇, 徐翀. 上海市医疗机构临床检验质量指标调查结果与分析[J]. 检验医学, 2018, 33(6): 567-571. |
[15] | 罗嘉俊, 丘文慧, 尹小毛, 吴海雄, 曾方银. 临床实验室设备管理系统开发与应用[J]. 检验医学, 2018, 33(5): 457-462. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||